 |
|||||||||||||||||||||
Dr. Andre A. Kulisz
|
|
San Antonio, Texas January 31, 2001 For immediate release: Dr. Andre A. Kulisz, Ph.D. a noted international expert on incontinence treatment and a developer of medical instrumentation announced the start of a development of the new-generation vaginal sensor for treatment of incontinence. Dr. Kulisz announced today that he and his development group started development of the new vaginal sensor for EMG biofeedback and electrical stimulation in incontinence treatment. The details of the new sensors are confidential. In his statement, however, Dr. Kulisz said: “the new device will shorten patients’ treatment and reduce cost substantially, giving the therapists a much-needed tool for cost- and time-efficient treatment. Offering long-lasting recovery at low cost, the new device will also provide welcome relief to the third-party payers burdened with high costs of repeatable surgical and pharmacological incontinence treatments and their side effects. The price will be compatible with the presently available sensors. Estimated development time is about 12 months.” The sensor will be approved as a 510(k) device. The US Government indicates in its official publication: ”Urinary Incontinence (UI) is a voiding dysfunction that affects approximately 13 million Americans, with the highest prevalence in the elderly in both community and institutional settings (National Kidney and Urologic Diseases Advisory Board, 1994). The high prevalence of UI and its significant adverse physical, psychological, and financial effects clearly justify more aggressive efforts to identify, evaluate, and treat UI in all settings… UI imposes a significant psychosocial impact on individuals, their families, and caregivers. UI results in a loss of… ability to maintain an independent lifestyle. Dependence on caregivers for activities of daily life increases as incontinence worsens. (Grimby, Milsom, Molander, et al., 1993; Harris, 1986; Noelker, 1987)… A recent estimate of the direct costs of caring for persons of all ages with incontinence is $11.2 billion annually in the community and $5.2 billion in nursing homes (based on 1994 dollars, Hu, 1994).” In addition to development of the Pelvitrax™ incontinence treatment method, Dr. Kulisz is also a noted expert in the area of medical device development and international clinical trials. He authored a number of medical devices and patents. Among them the intraurethral bladder control device, Autocath® 100, the only device of its kind approved in the countries of European Community for the full six-month use. He wrote a book on female incontinence “Drips, Leaks and Low Spirits, A Woman’s Guide to Bladder Control, Infections and Depression” whose second edition will be available soon. For more information contact Dr. Andre Kulisz at +1-210-402-3939
|